HomeMESO • NASDAQ
Mesoblast Ltd
$3.49
Pre-market:
$3.85
(10.32%)+0.36
Closed: Mar 28, 8:45:47 AM GMT-4 · USD · NASDAQ · Disclaimer
US listed security
Previous close
$3.49
Year range
$1.61 - $10.24
Market cap
317.61M USD
Avg Volume
2.97M
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
1.69M-11.72%
Operating expense
5.29M-14.26%
Net income
-16.27M33.56%
Net profit margin
-960.4224.73%
Earnings per share
——
EBITDA
-12.78M33.39%
Effective tax rate
0.31%—
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
77.55M14.69%
Total assets
670.28M0.33%
Total liabilities
161.55M-3.87%
Total equity
508.73M—
Shares outstanding
1.01B—
Price to book
6.98—
Return on assets
-4.96%—
Return on capital
-5.27%—
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-16.27M33.56%
Cash from operations
-13.29M19.25%
Cash from investing
-44.00K-29.41%
Cash from financing
15.80M885.29%
Net change in cash
3.12M117.44%
Free cash flow
-9.28M14.73%
About
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004. Wikipedia
Founded
2004
Employees
83
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu